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ABSTRACT 
DNA topoisomerases are ubiquitous enzymes that catalyse reactions that alter the 
topological state of DNA during the various processes of DNA metabolism including 
transcription, recombination, replication and chromosome segregation. Human cells 
exhibit a Type II enzyme termed DNA topoisomerase Ila. This enzyme is expressed at 
higher levels in proliferating cells due to an increased demand for chromosome 
separation. This is advantageous with respect to some of the drugs used in 
chemotherapy. These drugs can specifically target cancer cells by only being effective 
at high levels of topoisomerase Ila gene expression. However, the use of such drugs 
has been limited by both toxicity and the development of resistance. This resistance has 
been associated with a decrease in topoisomerase Ila at both protein and mRNA levels. 
The topoisomerase Ila minimal promoter is 650 base pairs in length and includes 
promoter elements such as inverted CCAAT boxes (ICBs) and GC rich regions. It has 
been determined that the ICB elements are of the most interest in terms of regulation of 
the topoisomerase Ila gene expression. Several studies have shown that the 
transcription factor NF-Y binds to ICB 1-4 of the topoisomerase Ila promoter and 
regulates transcription through these elements. 
This stucly aimed to determine the importance of NF-Y in the transcriptional regulation 
of topoisomerase Ila and to investigate the molecular mechanisms by which NF-Y 
associates with the topoisomerase Ila promoter with a particular focus on the inverted 
CCAAT box elements. The binding of NF-Y to oligonucleotides containing selected 
consensus elements of the topoisomerase Ila promoter was analysed (in vitro) by 
electrophoretic mobility shift binding assays. The importance of NF-Y in the 
regulation of topoisomerase Ila expression was analysed by functional assays, usmg 
reporter gene constructs in transiently transfected HeLa cells. 
The binding studies indicated that the flanking sequences affect the affinity of the 
transcription factor NF-Y for ICBl and ICB2 and that a regulatory element flanking 
ICB2 may aid in NF-Y binding to that element. Functional assays showed that NF-Y 
appears to act a negative regulator of topoisomerase Ila with its effect being entirely 
-due to interaction with ICB2. 
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Chapter One Introduction 
1.1 DNA Topoisomerases 
DNA Topoisomerases are ubiquitous enzymes that catalyse reactions that alter the 
topological state of DNA during the various processes of DNA metabolism; including 
transcription, recombination, replication and chromosome segregation (\,Vatt and 
Hickson, 1994 ). Consequently, these enzymes play an important role in the 
physiological functions of DNA (Watt and Hickson, 1994). 
Two types exist, type I and type II, classified due to their catalytic mechanism of action. 
Type I enzymes introduce single stranded breaks in DNA, pass an intact strand through 
the broken strand then reseal the break. Type II enzymes, in contrast make transient 
double stranded breaks in one segment of DNA and pass an intact duplex through the 
broken strand before resealing the break (Roca, 1995; Watt and Hickson, 1994). 
1.1.1 Prokaryotic DNA Topoisomerases 
Escherichia coli contains two type I DNA topoisomerases and two type II DNA 
topoisomerases. The two type I topoisomerases are topoisomerase I ( encoded by the 
topA/supX gene) and topoisomerase III (encoded by the topB gene) . Mutational 
analysis indicates that topoisomerase I is involved in transcription acting with DNA 
gyrase (a prokaryotic type II DNA topoisomerase) to catalyse changes in supercoiling 
ahead of and behind the translocating transcription machinery (Watt and Hickson, 1994; 
Austin and Fischer, 1990). Similar analysis of topoisomerase III suggests that it is 
involved in chromosomes stability and plasmid segregation (Watt and Hickson, 1994; 
Austin and Fischer, 1990). 
DNA gyrase (encoded by gyrA and gyrB genes) and topoisomerase IV (encoded by par 
C and par E genes) are the E.coli type II DNA topoisomerases. DNA gyrase appears to 
have multiple roles in vivo, including general supercoiling homeostasis, the initiation 
phase of DNA replication and chromosome partitioning (Watt and Hickson, 1994; 
Austin and Fischer, 1990). DNA gryase also appears to exhibit a specialised role in 
' 
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removing knots and catenanes generated by recombination (Watt and Hickson, 1994; 
Austin and Fischer, 1990). 
Unlike DNA gyrase, topoisomerase IV exhibits no supercoiling activity - its role 
appears to be in the resolution of catenanes generated by replication (Watt and Hickson, 
1994; Austin and Fischer, 1990). 
1.1.2 Yeast Topoisomerases 
Saccharomyces cerevisae exhibits two type I DNA topoisomerases and one type II 
DNA topoisomerase (Watt and Hickson, 1994; Austin and Fischer, 1990). The yeast 
topoisomerase I (the Topi gene product) is functionally homologous to E. coli topA and 
is able to relax both negatively and positively supercoiled DNA (Watt and Hickson, 
1994; Austin and Fischer, 1990). The second type I enzyme topoisomerase III (the 
Top3 gene product) shares high sequence homology with the E. coli topoisomerase III 
protein. Like its E. coli counter part, the yeast enzyme only relaxes negatively 
supercoiled DNA and forms a 5' phosphoryl end of cut DNA (Berger et al., 1996; Watt 
and Hickson, 1994). This mode of action is in contrast to all other type I enzymes, 
which form a 3' phospho-tyrosyl bond (Berger et al., 1996; Watt and Hickson, 1994). 
T opoisomerase III enzymes appear to have a significant role in repressing 
recombination and the maintaining of genome stability (Watt and Hickson, 1994). 
Yeast cells exhibit one type II DNA topoisomerase this single type II enzyme is 
topoisomerase II (Top2 gene product). Topoisomerase II lacks the supercoiling ability 
of DNA gyrase but like its prokaryotic counterpart, yeast topoisomerase II is essential 
for chromosome segregation and therefore cell survival (Berger et al., 1996; Watt and 
Hickson, 1994). 
1.1.3 Human DNA Topoisomerases 
Human cells express one type I DNA topoisomerase and two type II DNA 
topoisomerases. Human topoisomerase I appears to have a structure and function 
similar to the yeast type I DNA topoisomerase. Topoisomei-ase I relaxes negatively 
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supercoiled DNA and is thought to have roles in the initiation and elongation phases of 
DNA transcription and replication (Isaacs eta!., 1998; Watt and Hickson, 1994). Type 
II DNA topoisomerases in human cells exist in two ubiquitous forms - topoisomerase 
Ila (170 kDa) and topoisomerase np (180 kDa) . These are the products of different 
genes encoded on separate chromosomes (17q21-22 and 3p24 respectively) . An 
analysis of the genomic sequences indicates that the two genes have arisen via a recent 
gene duplication event (Isaacs et al., 1998; Watt and Hickson, 1994). 
Although these enzymes show similar catalytic activity, they differ biochemically in 
particular with respect to their thermal stabilities and differences in cell-cycle regulation 
and tissue-specific expression patterns (Isaacs et al., 1998; Watt and Hickson, 1994). 
The topoisomerase np product is found in a wide range of tissues including non-
proliferating tissues such as the brain, its transcription is constant throughout the cell 
cycle and is ubiquitously expressed in vitro and in vivo (Isaacs et al., 1998; Watt and 
Hickson, 1994). In contrast, topoisomerase Ila is found predominantly in proliferating 
tissues such as the spleen and bone marrow. Levels of topoisomerase Ila expression 
change during the cell cycle with low levels in Go/G 1 which increase throughout G 1 
and G2 and reach a maximum in S phase (Isaacs et al. , 1998). 
These differences between topoisomerase Ila and topoisomerase np indicate different 
functions with the p isoform thought to play a general role in DNA metabolism, 
whereas the strict cell cycle regulation of the a isoform suggest that it is likely to play a 
major role at mitosis (Isaacs et al., 1998; Watt and Hickson, 1994). Mutations in 
topoisomerase II which affect catalytic function, cause a loss of cell viability due to a 
failure to segregate newly replicated chromosomes at mitosis (Isaacs et al., 1998; Watt 
and Hickson, 1994). 
In mammalian cells, topoisomerase Ila and topoisomerase np are among the most 
important cellular targets for anticancer drugs. The topoisomerase Ila protein is of 
importance due to the enzyme being one of the best available markers of the 
proliferative state in vitro and in vivo (Isaacs et al., 1996). High levels oftopoisomerase 
II a gene expression correlate with relative sensitivity of cells to anticancer drugs 
whereas low levels confer drug resistance. For this reason, the understanding of 
topoisomerase Ila gene expression and its regulation i~ of great importance. 
3 
Information of such significance could lead to specific modulation of tumour 
chemosensitivity (Isaacs et al., 1996). 
1.2 Human Topoisomerase Ila 
Human topoisomerase Ila acts as a homodimer and catalyses a range of reactions on 
double-stranded DNA including relaxation., decatenation and unknotting (Watt and 
Hickson, 1994 ). The proposed mechanism for catalytic activity of topoisomerase Ila 
involves several steps. The catalytic cycle presented in Figure 1.1 from Berger et al 
1996. 
~-=y_;-: J ~ 
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Figure 1.1 - The catalytic cycle of human topoisomerase Ila taken from Berger et 
al., 1996. 
The cycle begins when the unliganded enzyme binds the G or gate segment ( 1) which 
induces a conformational change (2). Upon the binding of ATP (*) and the T or 
transported segment a series of further conformational changes occur and the G segment 
is cleaved (3) . Following these changes the ATPase segments of the enzyme dimerise 
and the T segment is transported through the break (4). Following transport of the T 
segment through the break the G segment is resealed and the T segment is released from 
the enzyme. 
The action of the catalytic cycle and the proliferation-dependent regulation of 
topoisomerase Ila along with its ability to generate double-stranded breaks in DNA and 
-the discovery of specific poisons or inhibitors to topoisomerase Ila. is advantageous with 
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respect to chemotherapy agents. A variety of chemotherapeutic agents can specifically 
target cancer cells by only being effective at high level of topoisomerase Ila. These 
drugs stabilise the cleaved intermediate in the catalytic cycle of topoisomerase Ila. 
When there are high levels of topoisomerase Ila in the cell, a greater number of 
cleavable complexes arise and cell death occurs. Cell death is due to the inability of the 
DNA repair apparatus to correct the large number of breaks in the DNA However, in 
cells with low levels of topoisomerase Ila few cleavable complexes are formed and the 
DNA repair apparatus is adequate leading to cell survival. The use of drugs that target 
topoisomerase Ila has been limited by the development of resistance. This resistance 
has been attributed to a decrease in topoisomerase Ila levels (Isaacs et al. , 1996). A 
number of factors can contribute to the production of high/low levels of topoisomerase 
Ila. These include gene expression/regulation, phosphorylation and post-transcriptional 
modification. This thesis focuses on the regulation of expression of human 
topoisomerase Ila and hence describes a study of some elements of the promoter and 
associated transcription factors. 
1.2.1 Human Topoisomerase Ila Promoter 
The 2.5 kb promoter of topoisomerase Ila has been isolated and cloned from a human 
placental genomic DNA library (Hochhauser et al, 1992) (see Appendix 1 for the 
sequence of the promoter). Analysis of the promoter revealed multiple sequence motifs 
as potential transcription factor binding sites (Figure 1.2) . Putative cis-acting elements 
within the minimal promoter of 617 bp including two Ge-rich boxes (Gel and GC2), 
five inverted CCAAT boxes (ICB 1-5), a consensus sequence for an activating 
transcription factor (ATF) binding site, a potential site for c-Myb (Myb) binding and a 
Myc/Max site. This -617 bp region is the minimal unit necessary for full promoter 
activity as identified by in vitro studies (Isaacs et al., 1998; Isaacs et al., 1996; 
Hochhauser et al., 1992). 
5 
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GC2 ICB5 ICB4 ATF ICB3 ICB2 ICBl GCl Myc/Max Myb 
-562 -385 -259 -226 -175 -108 --68 -51 -21 -12 
Figure 1.2: The Promoter of Topoisomerase Ila Promoter 
Some of these putative transcription factor binding sites have been implicated in both 
the regulation of topoisomerase Ila expression and in the development of resv,tance. 
Isaacs et al. , (1996) used confluence arrest of the cell cycle, which is associated with an 
active down-regulation of the topoisomerase Ila promoter, as a model system for 
topoisomerase Ila transcription. Although confluence arrest is not a common 
characteristic of tumour cells and the regulatory signals involved in confluence induced 
down-regulation are not likely to be identical to those associated with chemotherapy 
resistance, it is possible that the mechanism of down-regulation (for example repressor 
activity) is conserved. Using a 5' deletion series, Isaacs et al. , (1996) showed that 
confluence induced down-regulation of topoisomerase Ila promoter could be supported 
by a promoter fragment containing only 144 bp upstream of the + 1 site. This suggested 
that the repression event was mediated by transcription factors binding to elements 
within this region. Using site-specific mutagenesis, Isaacs et al. , (I 996) showed that 
down-regulation was driven from the ICB motif located at position -108 relative to the 
transcription start site (ICB2). When Isaacs et al., (1996) eliminated this ICB2 element 
by mutation in a promoter consisting of 617 bp upstream of the + 1 site, down-regulation 
at confluence no longer occurred. Mutations at the other putative transcription factor 
binding sites in the -144 region (I CB 1 and GC 1) had no effect on confluence arrest 
induced down-regulation of the topoisomerase Ila promoter. This evidence strongly 
suggested that ICB2 is the primary binding site involved in down-regulation of the 
topoisomerase Ila promoter governed by cell cycle arrest signalling. 
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1.2.2 Transcriptional Regulation of Human Topoisomerase I/a 
The most proximal binding motif relative to the transcription start site is a Myb binding 
site at position -12 (very close to the transcription start site) . Brandt et al (1997) 
showed that the c-myb proto-oncogene product caused cellular trans-activation of the 
topoisomerase Ila promoter via the Myb binding site in HL-60 cells. However, B-Myb 
a more widely expressed member of the Myb family was found to cause promoter up-
regulation in HeLa cells as well as in haematopoietic cells (Isaacs et al, 1998). 
Another transcription factor NF-M (a myeloid-specific member of the CCAAT 
enchancer-binding protein family required for activation of c-myb regulated target 
genes), activated the topoisomerase II a promoter in transfection studies using HL-60 
cells. However, the use of a dominant negative NF-M construct indicated that NF-M 
did not contribute to the endogenous regulation of topoisomerase Ila in these cells 
(Brandt et al, 1997). These results suggest that although NF-M is a potent and 
efficacious trans-activator of topoisomerase Ila ( ~38-fold over basal), NF-M does not 
appear to be involved in the endogenous transcriptional regulation of topoisomerase Ila. 
Another feature of the topoisomerase Ila promoter is a partial Myc/Max site. C-Myb 
acts as a heterodimer with a second transcription factor named Max. Together they 
have a role in growth regulation and have been implicated in activating a number of 
genes involved in cell cycle regulation (Isaacs et al., 1998, Hochhauser et al, 1992). 
The A TF transcription factor has been shown to bind to the topoisomerase Ila ATF site 
in vitro. Decreased levels of ATF transcription factor have been correlated with 
transcriptional repression of the topoisomerase Ila gene, during 12-O-tetradecanoyl 
phorbol 13-acetate (TP A)- induced differentiation ofHL-60 cells (Lim et al., 1998). 
Recently, a novel CCAAT binding protein has been described called ICBP90 (Inverted 
CCAAT Box Binding Protein, Mr 90kDa). ICBP90 bound to CCAAT elements from 
the topoisomerase Ila gene in in vitro binding assays (Hopfner et al., 2000). Analysis 
of the expression pattern of ICBP90 suggested that in tumour cells there is an enhanced 
expression of ICBP90. It has been suggested that this protein is involved in activation 
7 
of topoisomerase Ila. gene expression; however direct evidence for this activation has 
not been shown. 
Another CCAA T binding protein suggested to be involved in the transcriptional 
regulation of topoisomerase Ila. (via promoter activation) is the Y-box binding protein 
(YB-1 ). The decrease in expression of YB-1 due to the expression of antisense YB-1 
reduced activity of the topoisomerase Ila. promoter in vitro. In addition, YB-1 and 
topoisomerase Ila. were co-expressed in human colorectal carcinomas, supporting 
possible involvement of YB-1 in topoisomerase Ila. regulation (Shibao et al. , 1999). 
The gene and chromosome structure might also be important in topoisomerase Ila. 
transcriptional regulation. Structural alterations of one allele of the topoisomerase Ila. 
gene resulted in reduced topoisomerase Ila. mRNA and catalytic activity levels in a 
rnitoxantrone-resistant HL-60 cell line (Harker et al. , 1995). Methylation of the 
topoisomerase Ila. gene (Tan et al. , 1989) and histone acetylation (Adachi et al. , 2000; 
Currie et al., 1998) might also be involved in transcriptional regulation. Through 
histone acetylation, chromatin structures open and thus allow interactions between DNA 
and proteins (for example transcription factors) to occur, and methylation has been 
implicated as a mechanism for topoisomerase Ila. down-regulation in resistant cancers 
(Tan et al. , 1989). 
An Sp 1 consensus motif is found in the topoisomerase Ila. promoter at two positions 
Gel (-45 to -51) and GC2 (-554 to -563). Sp3 however, another Sp transcription 
factor of the Sp family has been found to bind only the GCl site. These transcription 
factors will be discussed in greater depth in section 1.2.3 . 
The human topoisomerase Ila. promoter has five inverted CCAAT (ICB) boxes. This 
type of motif is found in many human genes with wide-ranging functions. A number of 
proteins can specifically bind the CCAAT sequence, but their binding is influenced by 
the nature of flanking sequences. The ubiquitous transcription factor NF-Y is a 
CCAAT box binding protein that can recognise and bind ICBs. Within the 
topoisomerase Ila. promoter, NF-Y can recognise and bind ICBl-4 but not ICB5 
(Herzog and Zwelling, 1997). NF-Y and its association with the ICB elements of the 
topoisomerase Ila. promoter will be discussed in detail in sectiori 1.2.4. 
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1.2.3 Spl and Sp3 Transcription Factors 
Sp 1 is a ubiquitously expressed protein, belonging to a large multi-gene family of 
transcription factors (Spl, Sp2, Sp3 and Sp4), which binds GC boxes and can modulate 
gene expression by either activating or repressing transcription. Sp I contains 
glutamine-rich trans-activation domains and three Zn (II) finger motifs used to bind 
DNA (Kadonaga et al., 1987). Spl was originally identified as a transcription factor 
which binds and activates transcription from multiple GC-boxes in the simian virus 40 
(SV40) early promoter (Dynan and Tjian, 1983) and the thymidine kinase (TK) 
promoter (Jones et al., 1985). Since then, Sp 1 has been shown to be involved in the 
activation of expression of many different genes. The topoisomerase Ila promoter 
contains two GC boxes one distal (GC2) and one proximal (GCI). The classical Spl 
consensus is GGGGCGGGG. Both GC boxes within the topoisomerase Ila promoter 
share a high level of identity with the above consensus sequence, with the distal and 
proximal GC boxes being GGGGGCGGGG and GGGCGGG respectively. These 
differences may be relevant for binding activity such as affinity and specificity of tpe 
different members of the Sp transcription factor family. The GCI box of the 
topoisomerase Ila promoter is situated in close proximity to the transcription start site, 
therefore it is likely that the GC I box is involved in basal regulation of expression of 
topoisomerase Ha. 
To date there has been limited investigation into the role of Spl in the regulation of 
topoisomerase Ha expression. Kubo et al., (1995) showed that Spl levels were 
unchanged in topoisomerase Ila down-regulated etoposide resistant human KB cancer 
cells (these cells have decreased levels of topoisomerase Ha mRNA and therefore can 
be used for a study of topoisomerase Ila transcription), indicating that Spl is not 
involved in topoisomerase Ila down-regulation. 
Another study conducted by Yoon et al., (1999) using mouse fibroblast NIH3T3 cells, 
showed that the Sp I transcription factor was involved in cell proliferation-dependent 
regulation of the rat topoisomerase Ha gene promoter. Furthermore, transient 
transfections, with reporter plasmids containing mutations in the promoter region, were 
used to show that the GC2 box ( corresponding to GC I element of the human 
topoisomerase Ila promoter) was involved in the up-regulation of topoisomerase Ha 
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transcription in proliferating cells. Electrophoretic mobility shift assays (EMS As) with 
the GC2 element showed specific binding of the Sp 1 transcription factor (Yoon et al., 
1999). 
Other studies provide evidence for species-specific regulation of topoisomerase Ila 
despite sequence similarities. A study conducted by Adachi et al., (2000) showed that 
the proximal GC box did not appear to be responsible for the cell cycle-dependent 
regulation of the mouse topoisomerase Ila promoter. Mutations in this proximal GC 
box resulted in the induction of promoter activity, which suggests its involvement in the 
repression of basal activity. This result was further analysed utilising in vivo 
footprinting analysis. The results obtained showed that the protein binding to the GC 
box was cell cycle-dependent. In another study cell cycle-dependent regulation of 
human topoisomerase Ila GC 1 was independent of the element. However, in contrast 
with the study discussed above (Adachi et al. , 2000), loss of the GCI box resulted in 
reduction of S phase-specific activation of the topoisomerase Ila promoter (Falck et al., 
1999). The contrast between these results may be due to a number of factors such as 
experimental systems or species-specific elements and interactions with the 
topoisomerase Ila promoter. 
In all of these experiments the authors found that sequences upstream of the first GC 
box and the three ICB elements to -700 bp were not required for cell cycle-dependent 
regulation, however, they were required for maximal topoisomerase Ila expression. 
The human topoisomerase Ila promoter contains two GC boxes, which indicates 
interactions between these elements may be possible. Such interactions between distal 
and proximal Spl binding elements have been observed. The presence of a proximal 
and distal Sp 1 binding site may facilitate a looping effect and studies conducted showed 
that Sp I-Sp 1 protein interactions occur via looping of intervening cis-regulatory 
sequences (Courey et al. , 1989). 
In Chinese hamster topoisomerase Ila gene expression, GC boxes do not appear to be 
involved in transcriptional regulation. In support of this, in vitro footprinting analysis 
(Ng et al., 1995) confirmed that proteins do not bind to the GCI box. 
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From the experimental evidence described above it is likely that Sp 1 acts as an enhancer 
of transcription and that it regulates topoisomerase Ila expression via the GC boxes. 
However, its exact role in transcriptional regulation is still unclear. 
More evidence for topoisomerase Ila regulation from the GC boxes has been shown for 
Sp3, another member of the Sp family of transcription factors . Sp3 exhibits similar 
binding specificity to Spl (Hagen et al. , 1994), and was originally thought to be a 
competitive inhibitor of Sp 1 activated transcription. However, it was later found to 
possess stimulating properties as well. Sp3 has since been shown to be capable of both 
activating (Bigger et al. , 1997; Ding et al. , 1999; McEwen and Ornitz, 1998) and 
repressing (Li et al., 1998; Majello et al. , 1997) transcription. 
Several isoforms of Sp3 exist: l 10-l 15kDa, 70kDa and 60kDa species, which arise via 
internal translational initiation within the Sp3 mRNA (Kennett et al., 1997). Sp3 , in 
addition to DNA-binding domains and activation domains (similar to those in the Sp 1 
protein), contains an inhibitory domain (Suske, 1999). Kennett et al., (1997) suggested 
that the two small isoforms of Sp3 act as repressor molecules whereas the full length 
Sp3 isoform acts as an activator. However, Dennig et al., (1996) showed that this may 
not be the case as expression of full length Sp3 also repressed expression. 
Whether Sp3 acts as a repressor or an activator of transcription could depend on the 
context of binding. The structure and the arrangement of the recognition sites also 
appear to be important. Promoters containing a single binding site were activated 
whereas promoters containing multiple binding sites were not (Majello et al. , 1997). 
Kubo et al. , (1995) analysed topoisomerase Ila express10n m etoposide/teniposide-
resistant human epidermoid KB cells. A 300 bp upstream region of the topoisomerase 
Ila promoter which contains the Gel box alone as the Sp3 consensus site was used to 
drive the expression of the chloramphenicol acetyl transferase (CAT) reporter gene. 
Using northern blots and CAT reporter gene assays Kubo et al., (1995) demonstrated a 
3-fold increase in Sp3 levels in resistant cell lines compared with parental KB cells. 
The CAT activity was lower in resistant cell lines. These results suggest that Sp3 might 
may be involved in repressing the topoisomerase Ila promoter. However, Mo et al., 
( 1997) reported conflicting results using a merbarone-resistani cell line, which exhibits 
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transcriptional down-regulation of the topoisomerase Ila promoter. Using northern 
analysis Mo et al. , (1997) also showed that Sp3 was transcriptionally down-regulated in 
this cell line. In addition, they also showed that co-transfection of merbarone sensitive 
cells with Sp3 and with a topoisomerase Ila promoter-reporter construct resulted in the 
trans-activation of the topoisomerase Ila promoter by Sp3 . Co-transfection of resistant 
cell lines did not result in trans-activation. As the Sp3 expression vector was under 
control of a constitutive promoter, this finding cannot be explained by down-regulation 
of Sp3 levels . This suggests that Sp3 activity is dependent on cellular context. Sp3 
may be one of the components required for activation, and in a resistant cell line, the 
required components may not be available. This cell context-specific gene activation 
may also explain the contradictory results of Kubo et al. , (1995) and Mo et al., (1997). 
In addition, the reporter vector used by Mo et al. , (1997) was under control of a-577 to 
+60 topoisomerase Ila promoter fragment which contains the distal GC box. The 
presence of both GC elements might be important in determining the regulatory 
function of S p3 . 
Li et al. , (1998) described an example where proximal and distal GC boxes have 
different fuctions in gene regulation. The human transcobalamin II promoter contains a 
positive-acting distal GC box and a negative-acting proximal GC box. EMSA analyses 
showed that both GC boxes were recognised by Sp 1 and Sp3, and that co-transfection 
experiments using Sp 1 and Sp3 expression plasmids demonstrated that while Sp 1 
stimulated transcription, Sp3 acted to repress transcription. It is possible that the 
relative adundance of Spl and Sp3 in a cell regulates transcription oftopoisomerase Ila. 
The dual function of GC boxes can act as a switch to control transcription both 
positively and negatively, depending on the binding by associating activators and 
repressors, or Spl/Sp3 interactions. Li et al., (1998) speculated that Sp3 functions as a 
repressor through protein-protein interactions with components of the general 
transcription complex. Spl has also been shown to interact physically with Sp3 on the 
human plasminogen activator inhibitor-I gene, and this interaction resulted in 
synergistic activation of transcription (Li et al., 1998). 
Similarly to Spl , Sp3 transcription factor does not appear to be essential for 
topoisomerase Ila gene expression. Sp3-deficient mouse embryos were growth retarded 
and died at birth of respiratory failure (Bowman et al., 2000). The fact that the embryos 
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were able to form suggests that the topoisomerase Ila gene was expressed in null Sp3 
mice. 
1.2.4 Nuclear Factor-Y (NF-}'.) 
NF-Y (also known as CPI, CBF and ACF) is another transcription factor suggested to 
be important in the transcriptional regulation of the human topoisomerase Ila promoter. 
NF-Y is a CCAA T box binding protein and a heteromeric transcription factor 
comprised of three subunits: 42kDa NF-YA, 36kDa NF-YB and 40kDa NF-YC. It 
shares significant homology to the yeast transcriptional activators HAP2, HAP3 and 
HAPS. All three subunits are necessary for the sequence-specific DNA binding 
activity of NF-Y. NF-YB and NF-YC subunits interact with each other to form a stable 
heterodimer (Bellorini et al. , 1997). NF-Y contains two glutamine rich activation 
domains which share homology with each other and with the activation domain of the 
transcription factor Sp 1. NF-YA interacts with the NF-YB/C heterodimer and then 
binds to a CCAAT element. The hybrid surface that forms as a consequence of this 
trimerisation comprises the DNA binding domain which recognises the CCAAT box 
motif A study conducted by Dorn et al., (1987) of different CCMT elements revealed 
that specific flanking sequences are also required for high-affinity NF-Y binding. NF-Y 
is a ubiquitous transcription factor shown to be involved in the regulation of a number 
of different genes, including those of the major histocompatibility complex class II gene 
(Milos and Zaret, 1992), cdc (Zwicker et al. , 1995) and thyrnidine kinase (Chang and 
Liu, 1994). NF-Y is involved in different types of transcriptional activation: basal 
transcription, cell cycle-dependent, and inducible, tissue specific activation (Hu and 
Maity, 2000). In all characterised instances NF-Y has been shown to function as a 
transcriptional activator (Mantovani et al., 1992; Li et al., 1992; Maity et al., 1998). 
NF-Y itself is regulated by the differential expression of its subunits during growth and 
differentiation of different cell lineages (Maity et al., 1998). Alternatively spliced 
forms of NF-YA have been identified and although activation by these different 
isoforms seems to be unaffected, it is unknown how they interact with other factors (Li 
et al., 1992). This gives NF-Ya potential for dynamic transcriptional regulation. 
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Mechanisms for NF-Y mediated regulation are poorly understood. One of the best 
characterised examples of NF-Y regulation involves the activation of sterol dependent 
transcription of the famesyl diphosphate synthase and 3-hydroxyl-3-methylglutaryl-
coenzyme A (HMG-CoA) synthase genes (Jackson et al., 1995). The sterol responsive 
behaviour of the promoters of these genes was mapped by mutational analysis to an NF-
y binding inverted CCAAT box (Spear et al. , 1994). In this instance, NF-Y was found 
to mediate tissue specific sterol responsive element binding proteins ( activation by 
sterol status) by interacting with tissue specific sterol responsive element binding 
proteins (SREBPs). 
Several lines of evidence show that NF-Y is likely to be an important regulator of 
topoisomerase Ila transcription. In an in vivo study, a dominant negative NF-YA 
mutant was expressed stably in mouse fibroblast cells under the control of a 
tetracycline-responsive promoter (Hu and Maity, 2000). Dominant negative NF-YA 
inhibits binding of the NF-Y complex to DNA by sequestering the other components of 
the NF-Y heterotrimer, NF-YB and NF-YC (Mantovani et al. , 1994). This dominant 
negative analog of NF-YA makes it possible to study the role of NF-Y in different 
promoter systems in which its involvement is suggested. The expression of the mutant 
subunit resulted in the inhibition of cell growth. Northern blot analyses revealed a 
reduction of expression of the topoisomerase Ila gene, suggesting a direct role of NF-Y 
in the regulation of topoisomerase Ila expression (Mantovani et al. , 1994). 
The CCAA T box is one of the primary constituents of the topoisomerase Ila promoter. 
Specific binding ofNF-Y to the four most 3' CCAAT elements of the promoter has been 
shown in vitro (Herzog and Zwelling, 1997; Wang et al. , 1997; Isaacs et al., 1996), 
supporting the involvement of this transcription factor in topoisomerase Ila gene 
regulation. In these studies, the different ICB elements had different binding affinities 
for NF-Y, with ICB 1 having the highest and ICB2 having the lowest, while the most 
distal ICB (ICB5) bound a different unknown factor and showed virtually no affinity for 
NF-Y at all (Herzog et al., 1997). 
As introduced above, Isaacs et al., (1996) have shown that down-regulation of 
topoisomerase Ila in growth-arrested human MCF-7 breast carcinoma and mouse 
fibroblast Swiss 3T3 cells appears to be mediated by NF-Y acting on the ICB2, while 
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none of the other four ICBs appeared to be important for regulation of topoisomerase 
Ila at confluence arrest. Mutation of ICB2 completely abolished the down-regulation of 
the topoisomerase Ila promoter seen in confluence-arrested cells. After having 
identified the involvement of the ICB2 element in topoisomerase Ila promoter 
repression, Isaacs et al., (1996) conducted EMSA experiments to identify protein 
factors that bind this element. Antibody supershifts showed that the transcription factor 
NF-Y bound ICB2 and that this was the only transcription factor identified to bind in 
vitro to ICB2. Changes in NF-Y binding to ICB2, for example phosphorylation of NF-Y 
or availability of other factors interacting with NF-Y, may induce conformational 
changes in the promoter causing down-regulation of topoisomerase Ila gene expression 
in confluence-arrested cells. NF-Y was suggested to relieve repression by binding to 
ICB2 elements. 
ICB2 binding by NF-Y was shown to be increased in extracts from proliferating cells 
(Isaacs et al., 1996). Binding did occur in confluence arrested cell extracts, but to a 
lesser extent, indicating that levels of binding competent NF-Y were probably decreased 
in arrested cells (Isaacs et al. , 1996). It has also been shown that down-regulation of the 
topoisomerase Ila promoter in drug resistant cell lines is associated with a similar 
decrease in NF-Y complex formation (Wang H et al. , 1997). These observations 
suggest that NF-Y is indeed involved in down-regulation of the promoter and that ICB2 
is a critical element in the promoter for gene regulation. 
Isaacs et al. , (1996) carried out ribonuclease protection assays on RNA from the ICB2 
mutant constructs and found that while the hGH reporter rnRNA levels expressed from 
the promoter fragment carrying a mutated ICB l element were down-regulated in 
confluence-arrested cells, no such affect was observed in cells with the mutated ICB2 
constructs. These results along with other work of Isaacs et al., ( 1996) suggest that the 
ICB2 promoter element is functionally distinct from the other ICB elements. 
In contrast, the GC2 box from rat topoisomerase Ila promoter, but not an ICB element, 
was reported to mediate the regulation of topoisomerase Ila in a cell growth-specific 
manner. In addition, the binding activity of Sp 1 to the GC element increased during 
growth stimulation (Yoon et al., 1999). The different experimental methods and species 
may have contributed to this difference. Cell cycle arrest achieved by contact inhibition 
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(Isaacs et al., 1996) or serum starvation (Yoon et al., 1999) might cause different 
cellular events. In support of the work of Isaacs et al., (1996), Wang et al., (1997) 
showed that a decrease in NF-Y activity correlated with the down-regulation of 
topoisomerase Ila transcription in doxorubicin-resistant multiple myeloma cells. These 
observations suggest that topoisomerase Ila gene repression in confluence-arrested cells 
(and drug resistant cells) is due to a loss ofNF-Y binding. 
The ICB 1 element has been implicated in the heat shock-induced transcriptional 
activation of the topoisomerase Ila gene (Furukawa et al., 1998). Using promoter 
constructs ICB 1 was shown to be a requirement in the activation of topoisomerase Ila 
gene transcription after heat shock. EMSA analysis revealed reduced binding of a 
nuclear factor to ICB 1 after heat shock. These results suggest that repression of 
topoisomerase Ila transcription, under these experimental conditions, is mediated by a 
negative regulatory factor interacting with ICB 1. Sirniliar results were seen using 
NIH3T3 cells stably transfected with reporter plasmids containing various human 
topoisomerase Ila promoter fragments (Falck et al., 1999). Mutation of ICB 1 caused an 
increase in topoisomerase Ila transcription, demonstrating a repressive character for that 
element. Furthermore, EMSA experiments demonstrated a decrease in ICB 1 binding 
activity following serum addition. Antibody against NF-Y did not produce a supershift 
of the ICB 1 pro~e/protein complex. In another study, the transcriptional activities of 
luciferase reporter constructs were investigated by transient transfection experiments in 
two drug resistant human epidermoid KB cancer cell lines, K.BNP2 and KBNM4. The 
transcriptional activity of the -295 to +85 promoter was significantly down-regulated in 
these cells. Introduction of a mutation in ICB 1 abolished this down-regulation (Takano 
et al. , 1999). 
These experiments suggest repression of topoisomerase Ila is caused by binding of 
regulatory factor( s) to the ICB 1 element, activation of transcription occurs by 
decreasing the binding of that factor and allowing the binding of NF-Y to the ICB 
element(s). However, in vivo footprinting assays of the topoisomerase Ila gene 
promoter in KB, KBNP2 and KB/VM4 cells conducted by Takano et al., (1999), did 
not reveal any marked differences between the resistant and parental cell lines. 
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75% of the topoisomerase Ila promoter activity can be attributed to its five CCAAT 
boxes (Ng et al., 1995). However, these elements cannot be substituted for one another 
without disrupting promoter activity (Wang et al., 1997). Therefore, regulation from 
the ICBs in the topoisomerase Ila promoter is complex. To date, only NF-Y has been 
shown to bind four of the ICBs, including ICB2 which seems to direct confluence-
induced down-regulation of the promoter. It is possible that NF-Y may act as a 
transcriptional repressor of topoisomerase Ila at confluence arrest. 
It has been suggested that NF-Y, while generally acting as a transcriptional activator, 
has an architectural role in appropriately positioning other transcription factors . NF-Y 
appears to be unable to activate alone, but requires the presence of other activators 
nearby. Ronchi et al. , (1995) showed that NF-Y binds both major and minor grooves of 
DNA, and that the polarity of NF-Y binding may be essential for protein-protein 
interactions and may influence general promoter architecture. This suggests that 
different parts of the complex are specifically able to contact different classes of 
activators. Upon binding ofNF-Y, the DNA is distorted to a degree that depends on the 
adjacent sequences to the NF-Y binding sites ( distortion varies between 62 and 82 
degrees) . DNA bending is a possible mechanism for allowing distal and proximal 
regulatory elements to interact, facilitating transcriptional regulation. To date there are 
no known examples of NF-Y mediating a promoter repression effect, therefore the 
bending of topoisomerase Ila promoter at ICB2 may allow other protein factors binding 
further upstream to repress transcription. This would explain how a transcriptional 
activator such as NF-Y could direct down-regulation through promoter remodelling. 
Ronchi et al., 1995 suggest that this co-operative function is in part elicited by indirect 
facilitation of protein-protein interactions brought about by NF-Y-induced DNA 
distortions at the CCAAT element(s), however the exact mechanism of action 1s 
unknown. However, this model fails to account for the observation that a 
topoisomerase Ila promoter fragment, truncated at -144 (relative to the transcription 
start site), can still direct confluence-arrest induced down-regulation of topoisomerase 
Ila transcription (Isaacs et al., 1996). Clearly, more investigation into the role of ICB2 
and its interaction with NF-Y is required. 
Different mechanisms appear to be in place for the regulation of the mouse 
topoisomerase Ila gene transcription. In vivo footprinting analysis revealed cell cycle-
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independent protein binding to ICB elements. Changes in NF-Y binding did not 
account for the cell cycle-dependent topoisomerase Ila transcription. In addition, 
multiple ICB elements (at least two) were required for cell cycle-regulated transcription 
(Adachi et al., 2000). 
Although the CCAAT element alone is not able to activate transcription, it may be able 
to increase the activity of neighbouring promoter elements. NF-Y has been shown to 
interact with other transcription factors and co-activators regulating gene expression, in 
particular Spl (Roder et al. , 1999). Co-operation between NF-Y and Spl has been 
demonstrated in the regulation of several genes including the major histocompatability 
class II-associated invariant chain (Wright et al. , 1995), the p27K1Pl gene (Inoue et al. , 
1999), the hamster thymidine kinase gene (Sorensen and Wintersberger, 1999) and the 
fatty acid synthase gene (Roder et al. , 1997; Roder et al. , 1999). The promoters of these 
genes all have in common one or several Sp 1 bindng sites located in close proximity (20 
or 30 nucleotides) to an ICB. The molecular mechanism responsible for this co-
operation has been partly elucidated by the demonstration of interactions between NF-
y A and Sp 1, and the presence of specific protein-protein interaction domains in NF-YA 
and Sp 1 (Roder et al. , 1999). 
In the human topoisomerase Ila promoter, the proximal Sp 1 binding site is located 12 
nucleotides down-stream of the NF-Y binding site (ICB 1 element), making such an 
interaction possible, although this has not yet been demonstrated. 
The tumour suppressor protein p53 has been shown to inhibit the transcription of 
topoisomerase Ila in a fibroblast cell line by acting on the ICB 1 element (Wang et al. , 
1997). p53 is one of the most important regulators of the cell cycle in mammals, and is 
responsible for cell cycle arrest in response to DNA damage. Following on from Wang 
et al. , (1997), Suttle et al., (1998) showed that transfection of p53-deficient murine 
10(1) cells with wild-type p53 results in a decrease of NF-Y binding to ICB elements. 
Another study conducted by Sandri et al. , (1996) demonstrated that p53 inhibited 
topoisomerase Ila promoter activity in a human ovarian cell line. However, the action 
of p53 was independent of all characterised transcription factor binding sites. A 
possible mechanism for the down-regulation of topoisomerase Ila is that the treatment 
of cells with topoisomerase Ila targeting drugs causes DNA damage, by increased 
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incidents of cleavable complexes. The accumulation of these produces many double-
stranded breaks in DNA This induces p53 expression and subsequent down-regulation 
of topoisomerase Ila. In the cdc promoter, p53 was shown to repress cdc2 transcription 
via an ICB element. The complex formed at the CCAAT motif contained NF-Y. The 
mechanism of this repression has been suggested by Agoff et al., (1993), in a study 
where p53 repressed hsp70 transcription by an interaction with NF-Y. These results 
suggest that direct protein-protein interactions between p53 and NF-Y may decrease the 
binding affinity ofNF-Y and act to repress the topoisomerase Ila promoter. 
The activity ofNF-Y is also altered by the treatment of cells with an inhibitor of histone 
deacetylase (HDAC), trichostatin A (Jin and Scotto, 1998). Chromatin structure is 
modified by opposing activities: co-activators possessing histone acetyl-transferase 
(HAT) activity and co-repressors, recruiting HDAC. These HAT and HDAC activities 
alter histone acetylation status, thus resulting in the alteration of chromatin structure. 
Recently, NF-Y was shown to possess HAT activity in vivo through association with 
HATs, GCN5 (general control non-repressed protein 5) and PCAF (p300/CBP-
associated factor) (Currie, 1998). The overexpression of PCAF stimulated the human 
MDRl gene promoter via a direct interaction between NF-Y and PCAF (Jin and Scotto, 
1998). This interaction then resulted in the increase of NF-Y activation potential by 
opening the local chromatin structure and facilitating the access of other transcription 
factors to the promoter. 
Adachi et al. , (2000) suggested the involvement of acetylation in the regulation of 
mouse topoisomerase Ila as another mechanism for control of expression. These 
authors suggested that histone deacetylase plays a crucial role in the Go/GI-specific 
repression of the topoisomerase Ila promoter. NF-Y acts here to recruit histone acetyl-
transferases to the promoter region of topoisomerase Ila, stimulate histone acetylation 
and therefore activate transcription (in G2/M). 
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1.3 Topoisomerase Ila and Chemotherapy 
Beyond its essential physiological functions, topoisomerase Ila is the primary cellular 
target for a wide variety of anticancer drugs (Corbett and Osheroff, 1993). As 
mentioned previously the proliferative-dependent regulation of topoisomerase Ila and 
its catalytic mechanism of action coupled with the discovery of specific inhibitors and 
poisons make this enzyme a key target for chemotherapy. 
1.3.1 Topoisomerase II a as a Drug Target 
Although both topoisomerase isoforms interact with anticancer drugs in human cells, 
topoisomerase Ila is considered the primary target for a number of reasons. First, 
topoisomerase Ila has been shown to be more susceptible to topoisomerase II targeting 
drugs (Drake et al., 1989) and second, levels of topoisomerase Ila are elevated in 
proliferating cells whereas topoisomerase II~ levels are virtually constant throughout 
the cell cycle. 
Anticancer drugs can be classified into two catagories; topoisomerase II poisons and 
topoisomerase II catalytic inhibitors. Topoisomerase Il poisons act by intercalating 
DNA close to the active site of topoisomerases, stabilising the transient DNA:enzyme 
interaction complex forming a cleavable complex and preventing the enzyme from 
religating the cleaved DNA The initial cytotoxic event following treatment with a 
topoisomerase II poison is the formation of this cleavable complex which introduces 
high levels of protein-associated DNA breaks. These complexes are mutagenic and 
produce permanent double-stranded breaks in DNA These permanent breaks in the 
DNA then induce high levels of recombination with sister chromatid exchange, 
generation of large insertions and deletions, and the production of chromosomal 
aberrations and translocations (Chen and Liu, 1994; Corbett and Osheroff, 1993). 
When the strand breaks are present in high enough concentrations they result in cell 
death by necrosis or apoptosis (Chen and Liu, 1994). Topoisomerase II catalytic 
inhibitors function by inhibiting the enzyme function without forming cleavable 
complexes and as such inhibit other steps of the catalytic cycle (Andoh and Ishida, 
1998). 
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1.3.2 Drug Resistance to Topoisomerase II Targeted Drugs 
Drug resistance of cancer cells is one of the major problems in cancer chemotherapy 
and can arise at any step during the treatment process. Alterations in cell-cycle 
progression, drug transport, drug metabolism, and drug target as well as the processing 
of DNA damage have all been implicated in development of resistance to 
chemotherapeutic agents (Chen and Liu, 1994). Resistance to various topoisomerase 
targeting drugs has been observed with factors as candidates for the production of 
resistant cancer cells with respect to topoisomerase II targeted drugs these include 
MDRl over-expression, reduced topoisomerase II levels, drug resistant mutant 
topoisomerase, lengthened cell cycle time, and altered DNA repair functions (Chen and 
Liu, 1994). 
Dingemans et al. , (1998) state that both resistant cell lines and tumours show that down-
regulation of topoisomerase Ila expression is a factor correlated with resistance to 
topoisomerase II targeted drugs. Higher topoisomerase Ila levels were found in lines 
derived from topoisomerase II sensitive tumour types such as testis and cell lung cancer 
(Dingemans et al., 1998; Isaacs et al., 1995), when compared with resistant tumour 
types such as bladder and non-small cell lung cancers (Son et al., 1998; Towatari et al., 
1998). Direct evidence of a role for down-regulation of topoisomerase Ila expression in 
drug resistance has been shown by the use of antisense topoisomerase Ila RNA where 
reduced cellular expression of topoisomerase Ila protein and resistance to etoposide was 
demonstrated (Gudkov et al., 1993; Towatari et al. , 1998). Zhou et al. , (1999) also 
showed that transfer of a recombinant adenovirus expressing human topoisomerase Ila, 
into a resistant cell line increased sensitivity to the drug. 
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1.4 Aims of the Research 
Human topoisomerase Ila is not just important because of its functional role in the 
maintenance of DNA topology but also because it is a primary target in chemotherapy. 
Anticancer drugs can specifically target cancer cells by only being effective at high 
levels of topoisomerase Ila. However, the use of such drugs has been limited by the 
development of resistance to topoisomerase II targeting drugs. One possible 
mechanism for the development of resistance employed by a cancer cell is the decrease 
of topoisomerase Ila levels at both mRNA and protein levels (Isaacs et al., 1996). The 
maJor mechanism controlling topoisomerase Ila express10n 1s transcription. 
Transcription in eukaryotes is regulated through the binding of transcription factors to 
cis-elements in gene promoters. Current research focussed on the topoisomerase Ila 
promoter has left many unanswered questions and has suggested a role for the 
interactions between elements in the promoter in down-regulation which may have links 
to the development of resistance seen in cancer cells. One problem with published 
results thus far is the lack of functional studies concerning the interaction between the 
topoisomerase II a promoter and the transcription factor NF-Y. The primary aim of the 
research undertaken was to identify the molecular mechanisms involved in the 
transcriptional regulation of human topoisomerase Ila, with particular emphasis on the 
importance ofICB2 and its interaction with NF-Y. 
This aim was addressed as follows: 
1. EMSAs were performed using HeLa cell extracts to analyse the binding of NF-
y to DNA fragments containing elements of the topoisomerase Ila promoter. 
2. Functional assays were carried out using promoter-reporter constructs 
containing various mutations in the topoisomerase Ila promoter 
3. Functional assays were carried out using topoisomerase Ila promoter constructs 
in co-transfection experiments with the NF-YA dominant negative construct. 
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